We serve Chemical Name:poly (4-methoxy styrene) CAS:24936-44-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:poly (4-methoxy styrene)
CAS.NO:24936-44-5
Synonyms:4-METHOXYSTYRENE RESIN;MFCD00134007;4-vinylanisole homopolymer
Molecular Formula:C27H30O3
Molecular Weight:402.52500
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:220.7ºC at 760 mmHg
Density:0.962g/cm3
Index of Refraction:1.5967
PSA:27.69000
Exact Mass:402.21900
LogP:6.71370
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-METHOXYSTYRENE RESIN chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-vinylanisole homopolymer physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-METHOXYSTYRENE RESIN Use and application,4-vinylanisole homopolymer technical grade,usp/ep/jp grade.
Related News: Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: ��Within the top 20 global companies that spent the most on R&D in 2018, the top spender �C despite having the second smallest annual revenue of the group at $15.28 billion �C is Celgene, whose R&D spend was equal to 37% of its annual revenue. poly (4-methoxy styrene) manufacturer For example, an active ingredient to relieve pain is included in a painkiller. poly (4-methoxy styrene) supplier These include: high-barrier generic drug substances and commonly used generic drug substances. poly (4-methoxy styrene) vendor For example, an active ingredient to relieve pain is included in a painkiller. poly (4-methoxy styrene) factory Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: ��Within the top 20 global companies that spent the most on R&D in 2018, the top spender �C despite having the second smallest annual revenue of the group at $15.28 billion �C is Celgene, whose R&D spend was equal to 37% of its annual revenue.